Mdxhealth faces Nasdaq bid-price deficiency, must hit $1 per share by Dec. 28
MDXH•On June 30, 2026, Mdxhealth received a Nasdaq notification for failing to maintain the US$1.00 minimum bid price, citing a 30-business-day deficiency. The company has 180 days, until December 28, 2026, to regain compliance by achieving a $1.00 closing bid for 10 consecutive days or face delisting.
1. Nasdaq Notification Received
On June 30, 2026, Mdxhealth received a Notification Letter from Nasdaq’s Listing Qualifications Department stating it failed to maintain the US$1.00 per share minimum bid price under Nasdaq Listing Rule 5550(a)(2) after 30 consecutive business days below the threshold. This notice does not immediately impact the company’s Nasdaq Capital Market listing.
2. Compliance Deadline Established
Nasdaq has granted Mdxhealth a 180-calendar-day period, expiring December 28, 2026, to achieve a closing bid price of at least US$1.00 for 10 consecutive business days. Failure to meet this requirement could result in delisting or potential eligibility for an additional compliance period.
3. Potential Remediation Options
To restore compliance, Mdxhealth intends to closely monitor its closing bid price and may consider corporate actions, including a reverse share split of its outstanding ordinary shares, to elevate the per-share trading price above the US$1.00 threshold.
4. Business Operations Status
The listing deficiency notification does not affect Mdxhealth’s core operations in urology-focused precision diagnostics, and the company continues its genomic and molecular test offerings without interruption.
